<DOC>
	<DOCNO>NCT00267527</DOCNO>
	<brief_summary>This multicenter , randomize , placebo-controlled , double-blind , Phase 2 study . Patients treat total 12 week . There 6 week follow-up period treatment period end . Patients randomly assign low dose CJC 1295 , high dose CJC 1295 placebo . The objective ass compare efficacy , pharmacokinetics , safety , tolerability CJC 1295 patient human immunodeficiency virus ( HIV ) associate visceral obesity .</brief_summary>
	<brief_title>A Study Evaluate CJC 1295 HIV Patients With Visceral Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Obesity , Abdominal</mesh_term>
	<criteria>Age 1865 stable antiviral regimen Documented HIV infection HIV associate visceral obesity Body mass index ( BMI ) &gt; 24 &lt; 30 kg/m2 Diabetes Use growth hormone ( GH ) GH secretagogues Use systemic glucocorticoid , Use megestrol acetate appetite stimulant , Use general anorexigenic weightreducing agent , Use androgens , testosterone replacement therapy male hypogonadism physiological dos stable regimen least 6 month prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Treatment Experienced</keyword>
	<keyword>HIV Visceral Obesity</keyword>
</DOC>